更新于：2024-06-21
Macrogol 4000/Sodium Bicarbonate/Sodium Chloride/Potassium Chloride
聚乙二醇-4000/碳酸氢钠/氯化钠/氯化钾
更新于：2024-06-21
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (2002-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式ClNa |
InChIKeyFAPWRFPIFSIZLT-UHFFFAOYSA-M |
CAS号7647-14-5 |
查看全部结构式(4)
关联
10
项与 聚乙二醇-4000/碳酸氢钠/氯化钠/氯化钾 相关的临床试验An Open-label Study of AJG555 in 1-year-old Patients with Chronic Constipation
General Clinical Study of AJG555 in Pediatric Patients With Chronic Constipation
Assessing the quality of bowel preparation by addition of Movicol to standard bowel preparation regimen in patients undergoing routine colonoscopy: a randomized controlled trial
100 项与 聚乙二醇-4000/碳酸氢钠/氯化钠/氯化钾 相关的临床结果
登录后查看更多信息
100 项与 聚乙二醇-4000/碳酸氢钠/氯化钠/氯化钾 相关的转化医学
登录后查看更多信息
100 项与 聚乙二醇-4000/碳酸氢钠/氯化钠/氯化钾 相关的专利（医药）
登录后查看更多信息
25
项与 聚乙二醇-4000/碳酸氢钠/氯化钠/氯化钾 相关的文献（医药）2023-12-05Innovative surgical sciences
Paradox inflammatory reaction such as appendicitis epiploica and diverticulitis of the sigmoid colon under ongoing immunosuppression after previous liver transplantation (LTx)
作者: Croner, Roland S. ; Meyer, Frank ; March, Christine ; Petersen, Manuela ; Trautwein, Isabella
Abstract:
Objective:
Inflammatory reactions caused by immunosuppression appear a particular interesting disease due to its very specific and partly unclear etiopathogenesis.Based on clinical case-specific management experiences and selective references from the literature, the rare case of an acute intraabdominal inflammation as unusual complication or side effect (at the gastrointestinal [GI] tract) of the ongoing immunosuppressive medication using Mycophenolate mofetil and Tacrolimus after previous liver transplantation is to be illustrated.
Case presentation:
Medical history (hx): 1) Current: A 68-years old male patient underwent abdominal CT scan because of pain in the left lower abdomen with the suspicious diagnosis of diverticulitis leading to initiation of antibiotic therapy 24 h prior to the transferral to the own hospital for adequate liver transplantation (LTx) follow-up investigation. 2) Medication contained Sitagliptin 1 × 100 mg, Omeprazol 1 × 40 mg, Mesalazin 500 mg 3 × 2, Movicol 1 (on demand), Mycophenolate mofetil 2 × 500 mg, Tacrolimus 2 × 1 mg and Hydrochlorothiazid 1 × 2.5 mg. 3) Additional diagnoses included arterial hypertension, diabetes mellitus and urinary bladder diverticle. 4) Previous surgical intervention profile comprises resection of liver segments IV/V due to HCC (2011), orthotopic liver transplantation because of HCC caused by alcohol-induced liver cirrhosis (2013) and an intervertebral disc operation (2018). Physical examination of the abdomen revealed marked tenderness in the lower left quadrant. The abdominal wall was soft and there were no defensive tension and no peritonism. The patient was in good general condition and nutritional status. He was cardiopulmonarily stable and oriented to all qualities. Diagnostic measures showed a CRP of 38.0 (normal range, < 5) mg/L and a white blood cell count within normal range. Leading diagnoses were found using abdominal CT scan, which demonstrated an extended diverticulosis and an appendicitis epiploica within the immediate subperitoneal region of the left lower abdomen with an oval fat isodense structure in the region of the sigmoid colon with surrounding inflammatory imbibition and pronounced intestinal wall. Suspicious diagnosis was the 1st episode of an uncomplicated diverticulitis of the sigmoid colon associated with an appendicitis epiploica. Therapeutic approach was given by conservative therapy with infusion therapy, analgesia as well as inital “n. p. o.” and following initiation of oral nutrition. In addition, calculated antibiotic therapy with Cefuroxime and Clont was initiated. Clinical course was uneventful, with discharge on the eighth day of hospital stay with no pathological findings and substantial improvement in clinical and laboratory findings. Further advice consisted of clinical and laboratory follow-up control investigations by the family practitioner and nutritional counselling. In addition, a colonoscopy should be performed within four months.
Conclusions:
The described case i) is either one of the many side effects of the immunosuppressive medication Mycophenolate mofetil and Tacrolimus listed as “colonic inflammation” and “gastrointestinal inflammation”, respectively, or ii) can be considered an inflammatory response of a susceptible (gastro-)intestinal mucosa or the whole intestinal wall to microbes or microbial particles or agents caused by transplantation-associated immunosuppressive medication.
2023-09-01European journal of obstetrics, gynecology, and reproductive biology
Are we using best practice to guide laxative use in post-partum patients with obstetric anal sphincter injuries - A retrospective review.
Article
作者: Parange, Anupam ; Tucker, Julie ; Murphy, Elizabeth Mary Ann ; Do, Jee Eun ; Juszczyk, Karolina ; Hoang, Van Mt
OBJECTIVE:
Obstetric anal sphincter injury (OASI) is the leading cause of anal incontinence (AI) in young women. Laxatives are recommended to enhance recovery, however there are no consistent guidelines to guide best practice on the type, frequency, and dose of laxative should be used. This study aimed to evaluate the current use of laxatives following repair of OASIs, and to determine any association with AI. Study design A retrospective cohort study of 356 women who sustained OASIs between January 2016 and June 2020, at a single tertiary centre in Adelaide. Data regarding the type, dose and frequency of laxatives prescribed was extracted from each patient. The degree of OASIs was determined by clinical examination and endoanal ultrasound, and AI was measured by the St Marks incontinence score.
RESULTS:
Multiple combinations and classes of laxatives were prescribed including bulking agent (Metamucil and Fybogel), emollients (Coloxyl), and osmotic laxatives (lactulose and Movicol). Bulking agents were prescribed for 245 women (68.8%), which is contrary to the current recommendations based on two previous randomised controlled trials. AI reported by 51 (14.3%) women. There were no statistical differences between AI and laxative type, dose, or frequency.
CONCLUSION:
Considerable variation existed in laxatives prescription. Bulking agents was not associated with higher rates of AI. Further research is required to improve post-partum care in women following repair of OASIs.
2024-03-01Australian critical care : official journal of the Confederation of Australian Critical Care Nurses
A single-centre observational study of delayed defaecation in brain-injured patients in an adult intensive care unit
Article
作者: Parke, Rachael ; McConnochie, Rachael ; O'Brien, Anthony
BACKGROUND:
The incidence of delayed defaecation is high in enterally fed ventilated patients in intensive care units (ICUs). Those with brain injury may be harmed by increased intracranial pressure if delayed defaecation leads to abdominal distension. There are no studies evaluating a bowel guideline in the treatment of delayed defaecation in ventilated brain-injured ICU patients.
OBJECTIVE:
The objective of this study was to assess the incidence and clinical associations of delayed defaecation and level of compliance to an ICU bowel guideline.
METHODS:
Data were collected on ventilated adult patients with brain injury admitted for more than 3 days to one New Zealand ICU over a 2-year period.
RESULTS:
Data were analysed for 117 patients; 56 (48%) who defaecated within 3 days of ICU admission (Group one) and 61 (52%) with delayed defaecation after 3 days (Group two). Compliance with the bowel guideline was low. Only 1 of 61 patients who should have had a rectal examination did so, and only 7 of 61 patients who should have had an aperient on day 3 did so. All seven received Movicol®, which was not part of the guideline. Use of aperients and enemas was found to be associated with stool passage (odds ratio: 93; 95% confidence interval: 5.2-1668; p = 0.002). Patients with delayed defaecation had longer ICU stays (mean 7.1 ± 4 SD vs 5.9 ± 3 days, p = 0.07) and more often had high gastric residual volumes after day 4 (27/61 vs 14/56; p = 0.003). No differences were seen between the groups in the incidence of ventilator-associated pneumonia, bacterial infections, diarrhoea, vomiting, duration of mechanical ventilation, or mortality.
CONCLUSION:
Delayed defaecation was common, and compliance with the guideline was low. Movicol® and phosphate enemas were effective in stool production.
100 项与 聚乙二醇-4000/碳酸氢钠/氯化钠/氯化钾 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 便秘 | 日本 | 2018-09-21 | |
| 肠道准备 | 中国 | 2002-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 粪便嵌塞 | 申请上市 | 中国 | 2022-08-22 | |
| 慢性便秘 | 临床3期 | 日本 | 2016-11-15 | |
| 肠易激综合征 | 临床3期 | 捷克 | 2008-11-01 | |
| 肠易激综合征 | 临床3期 | 法国 | 2008-11-01 | |
| 肠易激综合征 | 临床3期 | 德国 | 2008-11-01 | |
| 肠易激综合征 | 临床3期 | 意大利 | 2008-11-01 | |
| 肠易激综合征 | 临床3期 | 波兰 | 2008-11-01 | |
| 肠易激综合征 | 临床3期 | 瑞典 | 2008-11-01 | |
| 肠易激综合征 | 临床3期 | 英国 | 2008-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 154 | PEG (PEG + E 13.125 g) | 齋範選鑰襯鑰願觸鏇壓(顧憲獵選鹽顧淵簾築願) = 淵築夢齋廠簾鹽構鏇衊 築醖壓襯製廠衊顧選簾 (淵壓襯範醖齋獵鏇廠積, 廠憲製窪餘築鹹窪繭鹹 ~ 齋夢範廠廠簾簾襯獵淵) 更多 | - | 2013-03-11 | ||
PEG (PEG + E 26.25 g) | 齋範選鑰襯鑰願觸鏇壓(顧憲獵選鹽顧淵簾築願) = 憲襯夢鏇範顧鏇糧鹹鏇 築醖壓襯製廠衊顧選簾 (淵壓襯範醖齋獵鏇廠積, 蓋憲願選鹹願鏇醖構窪 ~ 壓網選選遞簾膚衊蓋蓋) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用